Material Event (Form 8-K)

Item 8.01 Other Events.

As previously reported, Lifeward Ltd. (the "Company") received a deficiency letter (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") on August 5, 2025 indicating that, based on the closing bid price for the last 30 consecutive business days, the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a period of 180 calendar days, or until February 2, 2026 (the "Initial Compliance Date"), to regain compliance with the Bid Price Rule.

The Company did not regain compliance with the Bid Price Rule by the Initial Compliance Date. On February 3, 2026, the Company received a notification letter from Nasdaq indicating that the Company has been provided an additional period of 180 calendar days, or until August 3, 2026 (the "Extended Compliance Date"), to regain compliance with the Bid Price Rule. If, at any time before the Extended Compliance Date, the closing bid price for the Company's ordinary shares is at least $1.00 per share for a minimum of 10 consecutive business days as required under the Bid Price Rule, Nasdaq will provide written notification to the Company that it complies with the Bid Price Rule.

As previously reported, at the Extraordinary General Meeting of Shareholders on January 6, 2026, the shareholders of the Company approved a reverse share split with a split ratio in the range of 1-for-2 and 1-for-12 and the Board of Directors of the Company (the "Board") subsequently approved a split ratio of 1-for-12, with the timing and implementation of such reverse share split to be determined by the Board (the "Reverse Share Split"). The Company intends to monitor closely the closing bid price of its ordinary shares and to consider plans for regaining compliance with the Bid Price Rule, including but not limited to the Reverse Share Split. While the Company plans to review all available options, there can be no assurance that it will be able to regain compliance with the applicable rules during the additional 180-day compliance period.

If the Company does not regain compliance with the Bid Price Rule during the applicable cure period, Nasdaq will notify the Company that its ordinary shares are subject to delisting. The Company would then be permitted to appeal any delisting determination to a Nasdaq Hearings Panel. The Company's ordinary shares would remain listed on The Nasdaq Capital Market pending the Hearing Panel's decision after the hearing.